Iain Dukes, Theseus interim CEO

Or­biMed-backed The­seus de­buts with $100M round in hero­ic quest for 'pan-vari­ant' ki­nase in­hibitors

De­spite the promise of ki­nase in­hibitors in treat­ing rare tu­mors, nar­row ther­a­peu­tic tar­gets for most can­di­dates can halt ef­fi­ca­cy the mo­ment a pa­tient’s tu­mor cells mu­tate. Now, an Or­biMed-backed start­up will take a nine-fig­ure fundrais­ing round to ad­vance its pur­pose­ful­ly broad can­di­dates against treat­ment-re­sis­tant tu­mors.

Boston-based The­seus Phar­ma­ceu­ti­cals has bagged a $100 mil­lion Se­ries B round it will use to ad­vance a suite of “pan-vari­ant” ty­ro­sine ki­nase in­hibitors (TKI), in­clud­ing a lead com­pound tar­get­ing KIT-mu­tant gas­troin­testi­nal stro­mal tu­mors, the com­pa­ny said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.